Marine polyunsaturated fatty acids and cancer therapy

British Journal of Cancer

Volumn 108, Issue 3, 2013, Pages 486-492

  Vaughan, V C ^a   Hassing, M R ^a   Lewandowski, P A ^a  

^a DEAKIN UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DOCOSAHEXAENOIC ACID; FISH OIL; ICOSAPENTAENOIC ACID; POLYUNSATURATED FATTY ACID;

ANTINEOPLASTIC ACTIVITY; ANXIETY DISORDER; CACHEXIA; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER THERAPY; DRUG MECHANISM; FATIGUE; HUMAN; INFECTION; LENGTH OF STAY; NAUSEA; NONHUMAN; OUTCOME ASSESSMENT; PAIN; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR; SURVIVAL RATE; VITAMIN SUPPLEMENTATION;

ANIMALS; FATTY ACIDS, UNSATURATED; FISH OILS; HUMANS; NEOPLASMS;

EID: 84875231422     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.586     Document Type: Review

References (42)

1. AICR and WCRF Research (2007) Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective. American Institute for Cancer Research: Washington, DC, 2.
2. Alfano CM, Imayama I, Neuhouser ML, Kiecolt-Glaser JK, Smith AW, Meeske K, McTiernan A, Bernstein L, Baumgartner KB, Ulrich CM, Ballard-Barbash R (2012) Fatigue, inflammation, and omega-3 and omega-6 fatty acid intake among breast cancer survivors. J Clin Oncol 30: 1280-1287.
3. Arab K, Rossary A, Flourie F, Tourneur Y, Steghens JP (2006) Docosahexaenoic acid enhances the antioxidant response of human fibroblasts by upregulating gamma-glutamyl-cysteinyl ligase and glutathione reductase. Br J Nutr 95: 18-26.
4. Baracos VE, Mazurak VC, Ma DW (2004) n-3 Polyunsaturated fatty acids throughout the cancer trajectory: influence on disease incidence, progression, response to therapy and cancer-associated cachexia. Nutr Res Rev 17: 177-192.
5. Bayram I, Erbey F, Celik N, Nelson JL, Tanyeli A (2009) The use of a protein and energy dense eicosapentaenoic acid containing supplement for malignancy-related weight loss in children. Pediatr Blood Cancer 52: 571-574.
6. Bougnoux P, Hajjaji N, Ferrasson MN, Giraudeau B, Couet C, Le Floch O (2009) Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial. Br J Cancer 101: 1978-1985.
7. Calder PC (2002) Dietary modification of inflammation with lipids. Proc Nutr Soc 61: 345-358.
8. Cerchietti LC, Navigante AH, Castro MA (2007) Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer. Nutr Cancer 59: 14-20.
9. Chochinov HM (2001) Depression in cancer patients. Lancet Oncol 2: 499-505.
10. Colomer R, Moreno-Nogueira JM, Garcia-Luna PP, Garcia-Peris P, Garcia-de-Lorenzo A, Zarazaga A, Quecedo L, del Llano J, Usan L, Casimiro C (2007) N-3 fatty acids, cancer and cachexia: a systematic review of the literature. Br J Nutr 97: 823-831.
11. Das UN (2011) Essential fatty acids and their metabolites as modulators of stem cell biology with reference to inflammation, cancer, and metastasis. Cancer Metastasis Rev 30: 311-324.
12. Donohoe CL, Ryan AM, Reynolds JV (2011) Cancer cachexia: mechanisms and clinical implications. Gastroenterol Res Pract 2011: 601434.
13. Elia M, Van Bokhorst-de van der Schueren MA, Garvey J, Goedhart A, Lundholm K, Nitenberg G, Stratton RJ (2006) Enteral (oral or tube administration) nutritional support and eicosapentaenoic acid in patients with cancer: a systematic review. Int J Oncol 28: 5-23.
14. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12: 489-495.
15. Fearon KC, Barber MD, Moses AG, Ahmedzai SH, Taylor GS, Tisdale MJ, Murray GD (2006) Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol 24: 3401-3407.
16. Finocchiaro C, Segre O, Fadda M, Monge T, Scigliano M, Schena M, Tinivella M, Tiozzo E, Catalano MG, Pugliese M, Fortunati N, Aragno M, Muzio G, Maggiora M, Oraldi M, Canuto RA (2012) Effect of n-3 fatty acids on patients with advanced lung cancer: a double-blind, placebo-controlled study. Br J Nutr 108: 327-333.
17. Gerber M (2012) Omega-3 fatty acids and cancers: a systematic update review of epidemiological studies. Br J Nutr 107(Suppl 2): S228-S239.
18. Guarcello M, Riso S, Buosi R, d'Andrea F (2007) EPA-enriched oral nutritional support in patients with lung cancer: effects on nutritional status and quality of life. Nutr Ther Metab 25: 25-30.
19. Gurr M, Harwood J, Frayn K (2008) Lipid Biochemistry. An Introduction: Hoboken, Wiley-Blackwell.
20. Hall MN, Chavarro JE, Lee IM, Willett WC, Ma J (2008) A 22-year prospective study of fish, n-3 fatty acid intake, and colorectal cancer risk in men. Cancer Epidemiol Biomarkers Prev 17: 1136-1143.
21. Kim YJ, Chung HY (2007) Antioxidative and anti-inflammatory actions of docosahexaenoic acid and eicosapentaenoic acid in renal epithelial cells and macrophages. J Med Food 10: 225-231.
22. Mantovani G, Maccio A, Madeddu C, Gramignano G, Lusso MR, Serpe R, Massa E, Astara G, Deiana L (2006) A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress. Cancer Epidemiol Biomarkers Prev 15: 1030-1034.
23. Moses AW, Slater C, Preston T, Barber MD, Fearon KC (2004) Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. Br J Cancer 90: 996-1002.
24. Murphy RA, Clandinin MT, Chu QS, Arends J, Mazurak VC (2012) A fishy conclusion regarding n-3 fatty acid supplementation in cancer patients. Clin Nutr; e-pub ahead of print, 15 June 2012.
25. Murphy RA, Mourtzakis M, Chu QS, Baracos VE, Reiman T, Mazurak VC (2011) Supplementation with fish oil increases first-line chemotherapy efficacy in patients with advanced nonsmall cell lung cancer. Cancer 117: 3774-3780.
26. Murphy RA, Mourtzakis M, Chu QS, Baracos VE, Reiman T, Mazurak VC (2011) Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy. Cancer 117: 1775-1782.
27. Murphy RA, Yeung E, Mazurak VC, Mourtzakis M (2011) Influence of eicosapentaenoic acid supplementation on lean body mass in cancer cachexia. Br J Cancer 105: 1469-1473.
28. Osman H, Suriah A, Law E (2001) Fatty acid composition and cholesterol content of selected marine fish in Malaysian waters Food Chem 73: 55-60.
29. Raison CL, Miller AH (2003) Depression in cancer: new developments regarding diagnosis and treatment. Biol Psychiatry 54: 283-294.
30. Read JA, Beale PJ, Volker DH, Smith N, Childs A, Clarke SJ (2007) Nutrition intervention using an eicosapentaenoic acid (EPA)-containing supplement in patients with advanced colorectal cancer. Effects on nutritional and inflammatory status: a phase II trial. Support Care Cancer 15: 301-307.
31. Roodhart JMLG, Daenen EC, Stigter HJ, Prins J, Gerrits JM, Houthuijzen MG, Gerritsen HS, Schipper MJ, Backer M, van Amersfoort JS, Vermaat P, Moerer K, Ishihara E, Kalkhoven JH, Beijnen PW, Derksen RH, Medema AC, Martens AB, Brenkman EE, Voest (2011) Mesenchymal stem cells induce resistance to chemotherapy through the release of platinuminduced fatty acids. Cancer Cell 20: 370-383.
32. Russell ST, Tisdale MJ (2005) Effect of eicosapentaenoic acid (EPA) on expression of a lipid mobilizing factor in adipose tissue in cancer cachexia. Prostaglandins Leukot Essent Fatty Acids 72: 409-414.
33. Sawada N, Inoue M, Iwasaki M, Sasazuki S, Shimazu T, Yamaji T, Takachi R, Tanaka Y, Mizokami M, Tsugane S (2012) Consumption of n-3 fatty acids and fish reduces risk of hepatocellular carcinoma. Gastroenterology 142(7): 1468-1475.
34. Schmitz G, Ecker J (2008) The opposing effects of n-3 and n-6 fatty acids. Prog Lipid Res 47: 147-155.
35. Sullivan-Gunn MJ, Campbell-O'Sullivan SP, Tisdale MJ, Lewandowski PA (2011) Decreased NADPH oxidase expression and antioxidant activity in cachectic skeletal muscle. J Cachexia Sarcopenia Muscle 2: 181-188.
36. Sultan JSM, Griffin F, Di Franco JA, Kirby BK, Shenton CJ, Seal P, Davis YK, Viswanath SR, Preston N, Hayes (2012) Randomized clinical trial of omega-3 fatty acid-supplemented enteral nutrition versus standard enteral nutrition in patients undergoing oesophagogastric cancer surgery. Br J Surg 99: 346-355.
37. Taylor LAL, Pletschen J, Arends C, Unger U, Massing (2010) Marine phospholipids-a promising new dietary approach to tumor-associated weight loss. Support Care Cancer 18: 159-170.
38. Tisdale MJ (2009) Mechanisms of cancer cachexia. Physiol Rev 89: 381-410.
39. van der Meij BS, Langius JA, Spreeuwenberg MD, Slootmaker SM, Paul MA, Smit EF, van Leeuwen PA (2012) Oral nutritional supplements containing n-3 polyunsaturated fatty acids affect quality of life and functional status in lung cancer patients during multimodality treatment: an RCT. Eur J Clin Nutr 66: 399-404.
40. Wall R, Ross RP, Fitzgerald GF, Stanton C (2010) Fatty acids from fish: the anti-inflammatory potential of long-chain omega-3 fatty acids. Nutr Rev 68: 280-289.
41. Weed HG, Ferguson ML, Gaff RL, Hustead DS, Nelson JL, Voss AC (2011) Lean body mass gain in patients with head and neck squamous cell cancer treated perioperatively with a protein-and energy-dense nutritional supplement containing eicosapentaenoic acid. Head Neck 33: 1027-1033.
42. Wolyniak CJ, Brenna JT, Murphy KJ, Sinclair AJ (2005) Gas chromatographychemical ionization-mass spectrometric fatty acid analysis of a commercial supercritical carbon dioxide lipid extract from New Zealand green-lipped mussel (Perna canaliculus). Lipids 40: 355-360.